NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE – Single Technology Appraisal
Single Technology Appraisal
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
After very careful consideration, we have taken the decision to move the committee discussion for this appraisal to the meeting of the Highly Specialised Technologies Evaluation Committee on 14 February 2024. Please note that this topic will still be considered as a Single Technology Appraisal.
The discussion previously planned for 8 February 2024 will not be going ahead. The NICE website will be updated at 12pm (noon) tomorrow, Tuesday 12 December 2023.
This decision was taken to allow both this appraisal and the appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] – the same therapy in a different indication – to be considered by the same committee.
We will contact the selected experts separately regarding the change in date. If you have any questions or concerns please do get in touch.
Celia Mayers (she/her)
Project Manager, Technology Appraisals & HST